Results 181 to 190 of about 78,129 (305)

Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma [PDF]

, 2017
Bartlett, Nancy L, et al,, Ghobadi, Armin   +2 more
core   +2 more sources

NK cell-derived GZMB (granzyme B) suppresses glioblastoma radioresistance by blocking SDC1-mediated autophagosome maturation. [PDF]

Autophagy
Yan J, Feng R, Qin Q, Shen G, Tian M, Ling S, Zhou S, Li F, Xia X, Cao Y, Zeng L, Shao C, Sun X, Zheng W.   +13 more
europepmc   +1 more source

Infection control in the brain and the eye

Acta Ophthalmologica, EarlyView.
Abstract The Central Nervous System (CNS), comprising the brain and the eye, is considered to have a ‘privileged’ mechanism for dealing with immunological challenge (immune privilege, IP). CNS IP has been revealed through experiments using foreign protein antigens and cell and tissue alloantigens (grafts), but evidence for a role for IP in modulating ...
John V. Forrester, Paul G. McMenamin, Samantha J. Dando   +2 more
wiley   +1 more source

Development of a novel ¹⁸F-labeled radiotracer targeting granzyme B for imaging early tumor responses to immunotherapy. [PDF]

J Immunother Cancer
Xu H, Zhang J, Wei Z, Wang X, Yang MF, Yang X.   +5 more
europepmc   +1 more source

A reactive response to granzyme B [PDF]

Immunology & Cell Biology, 2010
Christensen, ME, Waterhouse, NJ
openaire   +2 more sources

Induction of IL‐9‐producing CD8+ T cells by ascochlorin derivatives

British Journal of Pharmacology, EarlyView.
A newly synthesised ascochlorin derivative, N184, induces small amounts of IL‐9‐producing CD8+ T cells. N184 improved the survival of CD8+ T cells and enhanced their antitumour activity, partially in an IL‐9‐dependent manner. The antitumour effect was completely dependent on IFNγ secretion rather than the cytotoxic activity of CD8+ T cells.
Natsumi Imano, Mikako Nishida, Miho Tokumasu, Weiyang Zhao, Nahoko Yamashita, Heiichiro Udono   +5 more
wiley   +1 more source

Granzyme B PET Imaging Enables Detection of CAR T-Cell Therapy Response in a Human Melanoma Mouse Model. [PDF]

Diagnostics (Basel)
Summer P, Bulmer N, Prabhu S, Gallon N, Larson RC, Maus MV, Mahmood U, Heidari P.   +7 more
europepmc   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

Granzyme B and melittin in cancer immunotherapy: molecular mechanisms and therapeutic perspectives in head and neck cancers. [PDF]

Front Immunol
Majchrzak A, Lewandowski F, Hrynkiewicz R, Poniewierska-Baran A, Bębnowska D, Niedźwiedzka-Rystwej P.   +5 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source